The Relationship Between Chronic Fatigue Syndrome and Chemical Exposure

References

• Fukuda K, Strause SE, Hickie I, Sharpe MC, Dobbins JG, Komaroff AL: The chronic fatigue syndrome: a comprehensive approach to its definition and study. Ann Intern Med 1994; 121: 953–9.
   PubMed Web of Science ®Google Scholar
• Schluderberg A, Starese SE, Peterson P, Blumenthal S, Komaroff AL, Spring SB: NIH conference chronic fatigue syndrome research: definition and medical out-come assessment. Ann Intern Med 1992; 177: 325–31.
   Google Scholar
• Komaroff AL, Buchwald D: Symptoms and signs of chronic fatigue syn-drome. Rev Infect Dis 1991; 13 (Suppl. 1): S8–11.
   Google Scholar
• Holmes GP, Kaplan JE, Glantz NM, Komaroff AL, Schonberger LB, Strause SE, Jones JF, Dubois RE, Cunningham-Rundles C, Pahwa S, Tosato G, Zegano LS, Purtilo DT, Brown N, Shcooley RT, Bris I: Chronic fatigue syndrome: a working case definition. Ann Intern Med 1988; 108: 387–9.
   PubMed Web of Science ®Google Scholar
• Ablashi DV: Summary. Viral studies of chronic fatigue syndrome. Clin Infect Dis 1994; 18: S130–133.
   Google Scholar
• Josephs SF, Henry B, Balachnadran N, Strayer D, Peterson D, Komaroff AL, Ablashi DV: HHV-6 reactivation in three patients with chronic fatigue syndrome. Lancet 1991; 337: 1346–7.
   PubMed Web of Science ®Google Scholar
• Jones JF, Ray CG, Minnich LL, Hick MJ, Kibler R, Lucus DO: Evidence for active Epstein-Barr virus infection in patients with persistent unexplained illnesses; elevated anti-early antigen antibodies. Ann Intern Med 1985; 102: 1–7.
   PubMed Web of Science ®Google Scholar
• Hettinger WC, Smith TF, Van Scoy RE, Spidzor PG, Forgacs P, Edson RS: Chronic fatigue syndrome and diagnostic utility of antibody to Epstein-Barr virus early antigen. JAMA 1988; 260: 971–3.
   PubMed Web of Science ®Google Scholar
• Levy JA, Greenspan D, Ferro F, Lennette ET: Frequent isolation of HHV-6 from saliva and high seroprevalence of the virus in the population. Lancet 1990; 335: 1047–50.
   PubMed Web of Science ®Google Scholar
• Archard LC, Bowles NE, Behan PO, Bell EJ, Doyle D: Post viral fatigue syn-drome: persistence of enterovirus RNA in muscle and elevated creatinine kinase. JR Soc Med 1988; 81: 326–29.
   PubMed Web of Science ®Google Scholar
• Miller NA, Carmichael HA, Hall FC, Calder BD: Antibody to Coxsackie B virus in diagnosing postviral fatigue syndrome. Br Med J 1991; 302: 140–3.
   PubMed Web of Science ®Google Scholar
• DeFreitas E, Hillard B, Cheney P, Bell DS, Kiggundu E, Sankey D, Wro-blewska Z, Palladino M, Woodward JP, Koppowski H: Retroviral sequences related to HTLVII in patients with chronic fatigue immune dysfunction syndrome. Proc Natl Acad Sci 1991; 88: 2922–26.
   PubMed Web of Science ®Google Scholar
• Secchier P, Zella D, Crowley RW, Gallo RC, Lusso P: Quantitative PCR for human herpes viruses 6 and 7. J Clin Microbiol 1995; 33:2124–30.
   PubMedGoogle Scholar
• Nicolson GL, Nicolson NL: Diagnosis and treatment of mycoplasmal infec-tions in Persian gulf war illness-CFIDS patients. Int J Occup Med Immunol Toxicol 1996; 5: 69–78.
   Web of Science ®Google Scholar
• Caligiuri M, Murray C, Buchwald D, Levine H, Cheney H, Peterson D et al.: Phenotypic and functional deficiency of natural killer cells in patients with chronic fatigue syndrome. J Immunol 1987; 139: 3306–13.
   PubMed Web of Science ®Google Scholar
• Morrison LTA, Behan WHM, Behan PO: Changes in natural killer cell pheno-types with patient with post-viral fatigue syndrome. Clin Exp Immunol 1991; 83: 441–6.
   PubMed Web of Science ®Google Scholar
• Klimas NG, Salavto FR, Morgan R, Fletcher MA: Immunologic abnormalities in chronic fatigue syndrome. J Clin Microbiol 1990; 28: 1403–10.
   PubMed Web of Science ®Google Scholar
• Lloyd A, Hickie I, Hickie C, Dwyer J, Wakefield D: Cell-mediated immunity in patients with chronic fatigue syndrome, healthy control subjects and patients with major depression. Clin Exp Immunol 1992; 8: 76–9.
   Google Scholar
• Chao CC, Janoff EN, Hu S, Thomas K, Gallaghe M, Tsang M et al.: Altered cytokine release in peripheral blood mononuclear cell culture from patients with chronic fatigue syndrome. Cytokine 1991; 3: 292–8.
   PubMed Web of Science ®Google Scholar
• Lloyd AR, Wakefield D, Boughton CR, Dwyer JM: Immunologic abnormali-ties in chronic fatigue syndrome. Med J Aust 1989; 151: 122–4.
   PubMed Web of Science ®Google Scholar
• Gin W, Christiansen FT, Peter JB: Immune function and the chronic fatigue syndrome. Med J Aust 1989; 151: 117–8.
   PubMed Web of Science ®Google Scholar
• Vojdani A, Ghoneum M, Brautbar N: Immune alteration associated with expo-sure to toxic chemical. Toxicology and Industrial Health 1992; 8: 231–46.
   PubMedGoogle Scholar
• Heuser G, Vojdani A, Heuser S: Diagnostic markers of multiple chemical sen-sitivity. In multiple chemical sensitivities addendum to biologic markers in immuno-toxicology. National Academy Press, Washington DC 1992; 117–138.
   Google Scholar
• Brautbar N, Vojdani A: Multiple chemical sensitivities facts or myth: Toxicol-ogy and Industrial Health 1992; 8 (Guest Editorial).
   Google Scholar
• Vojdani A, Campbell A: Immune functional abnormalities in patients with clinical abnormalities and silicone breast implants. Toxicology and Industrial Health 1992; 8: 415–430.
   PubMed Web of Science ®Google Scholar
• McConnachie P, Zahalsky AC: Immune alterations in humans exposed to the termiticide technical chlordane. Arch Env Health 1992; 47: 295–301.
   PubMed Web of Science ®Google Scholar
• Broughton A, Thrasher JD, Gard Z: Immunological evaluation of four arc welders exposed to fumes from ignited polyurethane (isocyanate) foam. Am J Ind Med 1988; 13: 463–72.
   PubMed Web of Science ®Google Scholar
• Denkhaus W, von Steldem D, Botzenhardt U, Konietzho H: Lymphocyte sub-populations in solvent-exposed workers, Int Arch Occup Environ Health 1986; 57: 109–115.
   PubMed Web of Science ®Google Scholar
• Byers V, Levin AS, Ozonoff DM, Baldwin RW: Association between clinical symptoms and lymphocyte abnormalities in a population with chronic domestic ex-posure to industrial solvent-contaminated water supply and a high incidence of leu-kemia. Cancer Immunol Immunother 1988; 27: 77–81.
   PubMed Web of Science ®Google Scholar
• Haustein, UF; Ziegler, V: Environmentally induced systemic sclerosis-like disorders. Int J Derm 1985; 24: 147–51.
   PubMed Web of Science ®Google Scholar
• Safran M, Paul TL, Roti E, Braverman LE: Environmental factors affecting autoimmune thyroid disease. Endocrinol Metab Clin North Am 1987; 16: 327–41.
   PubMed Web of Science ®Google Scholar
• Buchwald D, Garrity D, Pascualy R, Kith P, Ashley RA, Wener MH, Kid PG, Eaton JW, Ruse JE: Chronic Fatigue Syndrome. Toxicology Industrial Health 1992; 8: 157–72.
   PubMed Web of Science ®Google Scholar
• Buchwald D, Garrity D: Comparison of patients with chronic fatigue syn-drome, fibromyalgia, and multiple chemical sensitivities. Arch Int Med 1994; 154: 2049–53.
   PubMed Web of Science ®Google Scholar
• Ziem G, Done A: Chronic fatigue, fibromyalgia, and chemical sensitivity: overlapping disorders. Arch Intern Med 1995; 154: 1913.
   Google Scholar
• Ziem G, McTamney J: Profile of patients with chemical injury and sensitivity. Environ Health Perspect 1997; 105 (Suppl. 2): 417–36.
   Google Scholar
• Vojdani A, Ghoneum M, Choppa PC, Magtoto L, Lapp CW: Elevated apoptot-ic cell population in patients with chronic fatigue syndrome: the pivotal role of pro-tein kinase RNA. J of Int Med 1997; 242: 465–78.
   PubMed Web of Science ®Google Scholar
• Vojdani A, Mordechai E, Brautbar N: Abnormal apoptosis and cell cycle pro-gression in humans exposed to methyl tertiary-butyl ether and benzene contaminat-ing water. Human & Experimental Toxicol 1997; 16: 485–94.
   PubMed Web of Science ®Google Scholar
• Fraser A, McCarthy N, Evan GL: Biochemistry of cell death. Curr Opin in Neurobiol 1996; 6: 71–80.
   PubMed Web of Science ®Google Scholar
• Gerschenson LE, Rotello RJ: Apoptosis: a different type of cell death. FASEB J 1993; 6: 2450–55.
   Web of Science ®Google Scholar
• King KL, Schwartzman RA, Cidlowski JA: Apoptosis in life, death, and the cell cycle. Endocrinol & Metabol 1996; 3 (suppl A):93–7.
   Google Scholar
• Douglas RG, Martin SJ: The killer and the executioner: how apoptosis con-trols malignancy. Curr Opin in Immunol 1995; 7: 694–703.
   PubMed Web of Science ®Google Scholar
• Vaux DI, Strasser A: The molecular biology of apoptosis. Proc Natl Acad Sci USA 1996; 93: 2239–44.
   PubMed Web of Science ®Google Scholar
• Bursch W, Oberhammer F, Schulte-Hermann R: Cell death by apoptosis and its protective role against diseases. Tren Pharmacol Sci 1992; 13: 243–51.
   Google Scholar
• Ferbus D, Justesen J, Besancon R, Thang MN: The 2',5'-oligoadenylate syn-thetase has a multi-functional 2%5 '-nucleotidyltransferase activity. Biochem Biophys Res Commun 1981; 100: 847–56.
   PubMedGoogle Scholar
• Mordechai E, Kon N, Henderson EE, Suhadolnik RJ: Activation of the inter-feron-inducible enzymes, 2',5'-oligoadenylate synthetase and PKR by human T-cell leukemia virus type I Rex-response element. Virol 1995; 206: 913–22.
   PubMed Web of Science ®Google Scholar
• Zhou A, Hassel BA, Silverman RH: Expression cloning of 2-5-dependent RNase: a uniquely regulated mediator of interferon action. Cell 1993; 72: 753–65.
   PubMed Web of Science ®Google Scholar
• Floyd-Smith G, Slattery E, Lengyel P: Interferon action: RNA cleavage pat-tern of a (2'-5')-oligoadenylate dependent endonuclease. Science 1981; 212: 1020–32.
   Google Scholar
• Wreschner DH, James TC, Silverman RH, Kerr IM: Ribosomal RNA cleav-age, nuclease activation and 2-5A (ppp(A2'p)nA) in interferon-treated cells. Nucleic Acid Res 1981; 9: 1571–81.
   PubMed Web of Science ®Google Scholar
• Wreschner DH, McCauley JW, Skehel JJ, Kerr IM: Interferon action-sequence specificity of the ppp((A2/p)11A-dependent ribonuclease. Nature; 1991; 289: 414–17.
   Google Scholar
• Salzberg S, Hacohen D, David S, Dovrat S, Ahwan S, Gamliel KH, Birnbaum M: Involvement of interferon-system in the regulation of cell growth and differenti-ation. Scanning Microscopy 1990; 4: 479–489.
   PubMedGoogle Scholar
• Hubbell HR, Pequignot EC, Willis DH, Lee C, Suhadolnik RJ: Differential antiproliferative actions of 2'5 '-oligo A trimer core and its cordycepin analog on hu-man tumor cells. International J Cancer 1985; 36: 389–94.
   PubMed Web of Science ®Google Scholar
• Suhadolnik RJ, Reichenbach NL, Hitzges P, Adelson ME, Peterson DL, Cheney P, Salvato P, Thompson C, Loveless M, Muller WEG, Schroder HC, Strayer DR, Carter WA: Changes in the 2-5A synthetase/RNase L antiviral pathway in a con-trolled clinical trial with Poly(I)-Poly(C12U) in chronic fatigue syndrome. In Vivo 1994; 8:559–604.
   PubMedGoogle Scholar
• Suhadolnik RJ, Reichenbach NL, Hitzges P, Sobol RW, Peterson DL, Henry B, Ablashi DV, Carter WA, Strayer DR: Upregulation of the 2-5A synthetase/RNase L antiviral pathway associated with chronic fatigue syndrome. Clin Infectious Dis 1994; 18 (suppl. 1 S96): 104.
   Google Scholar
• Meurs E, Chong K, Galabru J, Thomas NSB, Kerr I, Williams BRG, Hovanes-sian AG: Molecular cloning and characterization of the human double-stranded RNA-activated protein kinase induced by interferon. Cell 1990; 62: 379–90.
   PubMed Web of Science ®Google Scholar
• Hovanessian AG, Laurent AG, Chebath J, Galabru J, Robert N, Svab J: Identi-fication of 69kD and 100kD forms of 2-5A synthetase in interferon treated human cells by specific monoclonal antibodies. EMBO J 1987; 6: 1273–80.
   PubMed Web of Science ®Google Scholar
• Clemens MJ, Elia A: The double-stranded RNA dependent protein kinase PKR: structure and function. J. Interferon and Cyto Res 1997; 17: 503–24.
   PubMed Web of Science ®Google Scholar
• Chelbi-Alix MK, Chousterman S: Ethanol induces 2'-5'-oligoadenylate syn-thetase and antiviral activities through interferon-0 production. J Biol Chem 1992; 267: 1741–45.
   PubMed Web of Science ®Google Scholar
• Lengyel P: Biochemistry of Interferons and their Actions. Annu Rev Biochem 1982; 51: 251–82.
   PubMed Web of Science ®Google Scholar
• Krishnan L, Baglioni C: Increased levels of (2'-5')-oligo(A) polymerase ac-tivity in human lymphoblastoid cells treated with glucocorticoids. Proc Natl Acad Sci USA 1980; 77: 6506–10.
   PubMed Web of Science ®Google Scholar
• Besancon F, Bourgeade MF, Justesen J, Ferbus D, Thang MN: Two inducers of cell differentiation enhance the 2'5'-oligoadenylate sythetase activity in MSV transformed cells. Biochem Biophys Res Commun 1981; 103: 16–24.
   PubMed Web of Science ®Google Scholar
• Saarma M, Toots U, Raukas E, Zhelkovsky A, Pivazian A, Neuman T: Nerve growth factor induces changes in (2'-5')-oligo(A) synthetase and 2'-phosphodiester-ase activities during differentiation of PC12 pheochromocytoma cells. Exp Cell Res 1986; 166: 229–36.
   PubMed Web of Science ®Google Scholar
• Zullo JN, Cochran BH, Huang AS, Stiles CD: Platelet-derived growth factor and double stranded ribonucleic acids stimulate expression of the same gene in 3T3 cells. Cell 1985; 43: 793–800.
   PubMed Web of Science ®Google Scholar